FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382023914> ?p ?o ?g. }

• W4382023914 abstract "The mRNA-based BNT162b2 (Pfizer-BioNTech) vaccine has been shown to elicit robust systemic immune response and confer substantial protection against the severe coronavirus disease (COVID-19), with a favorable safety profile in adolescents. However, no data exist regarding immunogenicity, reactogenicity and clinical outcomes of COVID-19 vaccines in adolescents with type 1 diabetes (T1D). In this prospective observational cohort study, we examined the humoral immune responses and side effects induced by the BNT162b2 vaccine, as well as, the rate and symptomatology of laboratory-confirmed COVID-19 vaccine breakthrough infections after completion of dual-dose BNT162b2 vaccination in adolescents with T1D and compared their data with those of healthy control adolescents. The new data obtained after the vaccination of adolescents with T1D could guide their further COVID-19 vaccination schedule.A total of 132 adolescents with T1D and 71 controls were enrolled in the study, of whom 81 COVID-19 infection-naive adolescents with T1D (patient group) and 40 COVID-19 infection-naive controls (control group) were eligible for the final analysis. The response of participants to the BNT162b2 vaccine was assessed by measuring their serum IgG antibodies to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 4-6 weeks after the receipt of first and second vaccine doses. Data about the adverse events of the vaccine was collected after the receipt of each vaccine dose. The rate of COVID-19 vaccine breakthrough infections was evaluated in the 6-month period following second vaccination.After vaccinations, adolescents with T1D and controls exhibited similar, highly robust increments in anti-SARS-CoV-2 IgG titers. All the participants in the patient and control groups developed anti-SARS-CoV-2 IgG titers over 1,050 AU/ml after the second vaccine dose which is associated with a neutralizing effect. None of the participants experienced severe adverse events. The rate of breakthrough infections in the patient group was similar to that in the control group. Clinical symptomatology was mild in all cases.Our findings suggest that two-dose BNT162b2 vaccine administered to adolescents with T1D elicits robust humoral immune response, with a favorable safety profile and can provide protection against severe SARS-CoV-2 infection similar to that in healthy adolescents." @default.
• W4382023914 created "2023-06-27" @default.
• W4382023914 creator A5002127339 @default.
• W4382023914 creator A5007448735 @default.
• W4382023914 creator A5012555717 @default.
• W4382023914 creator A5031183979 @default.
• W4382023914 creator A5040838059 @default.
• W4382023914 creator A5045743177 @default.
• W4382023914 creator A5054587268 @default.
• W4382023914 creator A5057124696 @default.
• W4382023914 creator A5067965320 @default.
• W4382023914 creator A5086670130 @default.
• W4382023914 creator A5088556840 @default.
• W4382023914 date "2023-06-26" @default.
• W4382023914 modified "2023-09-26" @default.
• W4382023914 title "Immunogenicity, safety and clinical outcomes of the SARS-CoV-2 BNT162b2 vaccine in adolescents with type 1 diabetes" @default.
• W4382023914 cites W1983868856 @default.
• W4382023914 cites W2045465986 @default.
• W4382023914 cites W2509566733 @default.
• W4382023914 cites W2521179614 @default.
• W4382023914 cites W3009906937 @default.
• W4382023914 cites W3022770671 @default.
• W4382023914 cites W3033130655 @default.
• W4382023914 cites W3037183278 @default.
• W4382023914 cites W3047978089 @default.
• W4382023914 cites W3101104830 @default.
• W4382023914 cites W3119134663 @default.
• W4382023914 cites W3126650156 @default.
• W4382023914 cites W3127817567 @default.
• W4382023914 cites W3135617626 @default.
• W4382023914 cites W3164720238 @default.
• W4382023914 cites W3173119869 @default.
• W4382023914 cites W3194553082 @default.
• W4382023914 cites W3195586393 @default.
• W4382023914 cites W3196748323 @default.
• W4382023914 cites W3209765937 @default.
• W4382023914 cites W3215303122 @default.
• W4382023914 cites W4200275675 @default.
• W4382023914 cites W4200441539 @default.
• W4382023914 cites W4205520565 @default.
• W4382023914 cites W4206453618 @default.
• W4382023914 cites W4206804309 @default.
• W4382023914 cites W4214836910 @default.
• W4382023914 cites W4220784865 @default.
• W4382023914 cites W4223975373 @default.
• W4382023914 cites W4224233017 @default.
• W4382023914 cites W4225868948 @default.
• W4382023914 cites W4226145347 @default.
• W4382023914 cites W4226268221 @default.
• W4382023914 cites W4238714725 @default.
• W4382023914 cites W4280568808 @default.
• W4382023914 cites W4293427389 @default.
• W4382023914 cites W4297243274 @default.
• W4382023914 cites W4306294828 @default.
• W4382023914 cites W4308518348 @default.
• W4382023914 cites W4310642350 @default.
• W4382023914 cites W4313236606 @default.
• W4382023914 cites W4316506165 @default.
• W4382023914 cites W4318562432 @default.
• W4382023914 doi "https://doi.org/10.3389/fped.2023.1191706" @default.
• W4382023914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37435175" @default.
• W4382023914 hasPublicationYear "2023" @default.
• W4382023914 type Work @default.
• W4382023914 citedByCount "0" @default.
• W4382023914 crossrefType "journal-article" @default.
• W4382023914 hasAuthorship W4382023914A5002127339 @default.
• W4382023914 hasAuthorship W4382023914A5007448735 @default.
• W4382023914 hasAuthorship W4382023914A5012555717 @default.
• W4382023914 hasAuthorship W4382023914A5031183979 @default.
• W4382023914 hasAuthorship W4382023914A5040838059 @default.
• W4382023914 hasAuthorship W4382023914A5045743177 @default.
• W4382023914 hasAuthorship W4382023914A5054587268 @default.
• W4382023914 hasAuthorship W4382023914A5057124696 @default.
• W4382023914 hasAuthorship W4382023914A5067965320 @default.
• W4382023914 hasAuthorship W4382023914A5086670130 @default.
• W4382023914 hasAuthorship W4382023914A5088556840 @default.
• W4382023914 hasBestOaLocation W43820239141 @default.
• W4382023914 hasConcept C126322002 @default.
• W4382023914 hasConcept C134018914 @default.
• W4382023914 hasConcept C187212893 @default.
• W4382023914 hasConcept C197934379 @default.
• W4382023914 hasConcept C203014093 @default.
• W4382023914 hasConcept C22070199 @default.
• W4382023914 hasConcept C2777704310 @default.
• W4382023914 hasConcept C2779134260 @default.
• W4382023914 hasConcept C2780791431 @default.
• W4382023914 hasConcept C2780801004 @default.
• W4382023914 hasConcept C2780868878 @default.
• W4382023914 hasConcept C2781232474 @default.
• W4382023914 hasConcept C3008058167 @default.
• W4382023914 hasConcept C524204448 @default.
• W4382023914 hasConcept C555293320 @default.
• W4382023914 hasConcept C71924100 @default.
• W4382023914 hasConcept C8891405 @default.
• W4382023914 hasConceptScore W4382023914C126322002 @default.
• W4382023914 hasConceptScore W4382023914C134018914 @default.
• W4382023914 hasConceptScore W4382023914C187212893 @default.
• W4382023914 hasConceptScore W4382023914C197934379 @default.
• W4382023914 hasConceptScore W4382023914C203014093 @default.
• W4382023914 hasConceptScore W4382023914C22070199 @default.

• next